^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Praluent (alirocumab)
i
Other names: SAR 236553, REGN 727, REGN-727, SAR-236553
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Regeneron, Sanofi
Drug class:
PCSK9 inhibitor
Related drugs:
26d
PCSK9 Inhibition Protects Against Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetes Rats Via Suppressing Inflammation and Apoptosis. (PubMed, Anatol J Cardiol)
Alirocumab and atorvastatin effectively attenuated myocardial I/R injury in T2DM by modulating lipid metabolism, inflammation, and apoptosis. Diabetes substantially intensified I/R-induced cardiac injury, underscoring the importance of metabolic control in cardioprotection. #Means they contributed equally to the article.
Preclinical • Journal
|
IL6 (Interleukin 6) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • CASP3 (Caspase 3) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
atorvastatin • Praluent (alirocumab)
1m
Alirocumab therapy effectively suppresses colorectal cancer cell Growth and invasion in nude mouse liver-PCSK9 is a key driver of PI3K/Akt/p-Bad-mediated cell proliferation and antiapoptotic signaling. (PubMed, Int J Surg)
Alirocumab-facilitated 5-FU therapy effectively suppresses PCSK9-promoted CRC proliferation/growth/invasion, highlighting that alirocumab therapy may be an alternative choice of adjuvant therapy in combination with surgery or chemotherapy.
Preclinical • Journal
|
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • DLD (Dihydrolipoamide Dehydrogenase)
|
5-fluorouracil • Praluent (alirocumab)
3ms
PCSK9-PROVE: PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy (clinicaltrials.gov)
P2/3, N=478, Not yet recruiting, Nanfang Hospital, Southern Medical University
New P2/3 trial
|
Repatha (evolocumab) • Praluent (alirocumab)
4ms
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung (clinicaltrials.gov)
P2, N=60, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting | Trial completion date: Jan 2029 --> Jan 2027 | Trial primary completion date: Jan 2027 --> Jan 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MET exon 14 mutation
|
Libtayo (cemiplimab-rwlc) • Praluent (alirocumab)
5ms
The use of monoclonal antibodies for the treatment of atherosclerosis: current status and prospects. (PubMed, Cell Mol Biol (Noisy-le-grand))
Notably, anti-PCSK9 antibodies like alirocumab and evolocumab have demonstrated significant reductions in LDL-C levels and cardiovascular events in large-scale clinical trials. Overall, monoclonal antibody therapy represents a significant advancement in the management of atherosclerosis, with ongoing research aimed at optimizing efficacy, safety, and accessibility. Future directions include the development of novel mAbs and combination therapies to further improve cardiovascular outcomes in patients with atherosclerotic disease.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta)
|
Repatha (evolocumab) • Praluent (alirocumab)
6ms
STaRT: Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia (clinicaltrials.gov)
P=N/A, N=2382, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
simvastatin • Repatha (evolocumab) • atorvastatin • Praluent (alirocumab)
7ms
PERFECT-AMI: Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (clinicaltrials.gov)
P4, N=20, Recruiting, Shanghai Tong Ren Hospital | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Dec 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
Praluent (alirocumab)
7ms
PERI-DYS: Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (clinicaltrials.gov)
P=N/A, N=1695, Completed, GWT-TUD GmbH | Active, not recruiting --> Completed
Trial completion
|
Repatha (evolocumab) • Praluent (alirocumab)
7ms
Improving Lipid Optimization Quality and Treatment Options in ASCVD (clinicaltrials.gov)
P4, N=300, Not yet recruiting, Brigham and Women's Hospital
New P4 trial
|
Repatha (evolocumab) • Praluent (alirocumab)
8ms
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) (clinicaltrials.gov)
P3, N=140, Recruiting, University of California, San Francisco | Trial completion date: Jul 2025 --> Aug 2026 | Trial primary completion date: Jul 2024 --> Aug 2025
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule) • CRP (C-reactive protein)
|
Praluent (alirocumab)
8ms
Safety and efficacy of alirocumab in improving early neurologic deterioration in patients with branch atheromatous disease :a multicenter, randomized, parallel controlled clinical trial (ChiCTR2500097071)
P=N/A, N=284, Not yet recruiting, Ganzhou people's hospital; Ganzhou people's hospital
New trial
|
Praluent (alirocumab)
9ms
TOPICAL-MRI: Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis (clinicaltrials.gov)
P2, N=60, Active, not recruiting, Chang Gung Memorial Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Aug 2024 --> Apr 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
Praluent (alirocumab)
Share via
